Proactive monitoring provides the information you need to catch changes in cancer early, before treatment resistance occurs
A blood test while on your first treatment for metastatic breast cancer may help uncover early signals of cancer changing before they could cause progression (start to grow and spread).
GET PROACTIVE MONITORING SUMMARY PDF
You and your doctor can use this information to discuss your treatment plan for HR+/HER2- metastatic breast cancer.
Ask your doctor about repeat testing for ESR1 mutations
Jump to topics on this page:
How can metastatic breast cancer change over time?
How can metastatic breast cancer change over time?
The recommended first treatment for HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative) metastatic breast cancer (mBC) includes a type of hormone therapy, called an aromatase inhibitor, and a CDK4/6 inhibitor (cyclin-dependent kinase 4/6 inhibitor).
First hormone therapy
(aromatase inhibitors)
anastrozole exemestane letrozole
CDK4/6 inhibitors
abemaciclib palbociclib or ribociclib
Together, these therapies help control
metastatic breast cancer from growing
and spreading.
Over time, metastatic breast cancer can change in response to your first hormone therapy. These changes may cause the treatment to stop working eventually, allowing the cancer to progress (start to grow and spread).
Traditionally, a scan showing progression has been required for a doctor to recommend a cancer treatment change. Advancements in testing for ESR1 mutations may show signals that treatment is becoming less effective, detecting them proactively, before progression, so you and your doctor can discuss options proactively.
- Aromatase inhibitor:
- a type of hormone therapy that treats some breast cancers by blocking estrogen—a hormone that tells cancer to grow. Common types of aromatase inhibitors include anastrozole, letrozole, or exemestane.
- CDK4/6 inhibitor:
- cyclin-dependent kinase 4/6 inhibitor, a type of cancer treatment that blocks cell division (palbociclib, ribociclib, or abemaciclib).
- ESR1 mutation:
- estrogen receptor 1 mutation, a change to the ESR1 gene that could cause breast cancer cells to be resistant to some hormone therapies.
- HER2- :
- human epidermal growth factor receptor 2 negative. Your HER2 status can help determine what treatments may be appropriate for you.
- HR+ :
- hormone receptor positive. Your HR status can help determine what treatments may be appropriate for you.
- Metastatic:
- cancer that has spread from the original tumor to other parts of the body.
- Progression:
- when cancer starts growing or spreading.

Are ESR1 mutations a signal that cancer is changing?
An ESR1 mutation is a change in the cancer's DNA that can develop while on hormone therapy. Having an ESR1 mutation makes it more likely that your first hormone treatment (aromatase inhibitor) for metastatic breast cancer could stop working.
ESR1 mutations are rarely detected at diagnosis. But over time, ~4 out of 10 people with metastatic breast cancer can develop an ESR1 mutation during their first hormone therapy.
Previously, ESR1 mutation testing happened after progression, with a liquid biopsy through a blood test. But, scientists have discovered advancements that allow monitoring before they could cause cancer to progress (start to grow and spread).


Over time,
~ 4 out of 10 out of 10
people with metastatic breast cancer can develop an ESR1 mutation.

How is proactive monitoring an advancement in catching cancer changes before progression?
Proactive monitoring is an advancement in metastatic breast cancer care. You can speak to your doctor about cancer changes and your treatment plan before progression, helping you stay involved in what may happen next.
Proactive monitoring in action
Proactive monitoring is a part of your regular monitoring routine

Your doctor will perform a blood test approximately every 3 months to look for ESR1 mutations

As part of this routine care, your doctor will repeat testing to determine if any adjustment in your treatment plan may be needed
What else is important to know about proactive monitoring for metastatic breast cancer treatment?
Proactive monitoring consists of a blood test that fits into your regular monitoring routine (approximately every 3 months), making it possible to catch these changes early.
These blood tests are also known as ctDNA (circulating tumor DNA) tests, because they look for traces of cancer DNA that is shed into the bloodstream. ctDNA tests may have many uses, including determining if a treatment is working.
Your guide to looking ahead for early signals of progression
Short on time?
Take this information with you:
How can metastatic breast cancer change over time?
The recommended first treatment for HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative) metastatic breast cancer (mBC) includes an aromatase inhibitor, a type of hormone therapy, plus a CDK4/6 inhibitor.
Aromatase inhibitors:
- anastrozole
- exemestane
- letrozole
CDK4/6 inhibitors:
- palbociclib
- ribociclib
- abemaciclib
Together, these therapies help control metastatic breast cancer from growing and spreading.
Over time, metastatic breast cancer can change in response to hormone therapy. These changes may make treatment less effective and eventually allow the cancer to progress.
Traditionally, a scan showing progression has been required for a doctor to recommend a cancer treatment change. Advancements in testing for ESR1 mutations may show signals that treatment is becoming less effective, detecting them proactively, before progression, so you and your doctor can discuss options proactively.
DID YOU KNOW?
An ESR1 mutation can be an early signal that metastatic breast cancer is changing.
What does an ESR1 mutation mean?
An ESR1 mutation is a change in the cancer's DNA that can develop during hormone therapy. If an ESR1 mutation develops, your first hormone treatment (aromatase inhibitor) may be more likely to stop working.
ESR1 mutations are rarely detected at diagnosis. But over time, around 4 out of 10 people with metastatic breast cancer can develop an ESR1 mutation during their first hormone therapy.
Previously, ESR1 mutation testing happened after progression, with a liquid biopsy through a blood test. But scientists have discovered advancements that allow monitoring before they could cause cancer to progress.
How can proactive monitoring help?
Proactive monitoring gives your doctor a way to look for ESR1 mutations during your regular metastatic breast cancer care.
Talk with your doctor about whether blood testing during treatment may be appropriate for you and your treatment goals.
Part of your regular monitoring routine
Your doctor may incorporate ESR1 mutation testing into your ongoing care.
A blood test approximately every 3 months
Your doctor will perform a blood test approximately every 3 months to look for ESR1 mutations.
Helping inform treatment decisions
Your doctor will repeat testing as part of your routine care to determine whether an adjustment to your treatment plan may be needed.
Talk with your care team about detecting changes earlier
Consider asking your doctor:
- Can my cancer change during my first treatment for metastatic breast cancer?
- What would an ESR1 mutation mean for my metastatic breast cancer?
- Could proactive monitoring be part of my care plan?
- If an ESR1 mutation is found, how might it affect my treatment plan?
Ask your doctor about proactive monitoring for ESR1 mutations.
SUMMARY PDF
Continue learning about testing for ESR1 mutations proactively and looking ahead for signals of metastatic breast cancer progression
Stay connected
Thank You!






